A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Inclusion criteria

• Eligible participants must have the following at both screening and baseline:

• A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months
• Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet
• BSA involvement of ≥0.5% on the face
• F-VASI ≥0.5 and T-VASI ≥3, and
• Either active or stable disease at both screening and baseline

Exclusion criteria

• Participants who have other types of vitiligo that are not considered active or stable vitiligo
• Currently have active forms of other disorders of pigmentation
• Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
• Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
• Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening
• Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data
• Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve